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ABSTRACT 
 
Malignant gliomas are intrinsic brain tumors with a dismal prognosis. They are well-adapted 
to hypoxic conditions and poorly immunogenic. NKG2D is one of the major activating 
receptors of natural killer (NK) cells and binds to several ligands (NKG2DL).  
Here we evaluated the impact of miRNA on the expression of NKG2DL in glioma cells 
including stem-like glioma cells. Three of the candidate miRNA predicted to target 
NKG2DL were expressed in various glioma cell lines as well as in glioblastomas in vivo: 
miR-20a, miR-93 and miR-106b. LNA inhibitor-mediated miRNA silencing up-regulated 
cell surface NKG2DL expression, which translated into increased susceptibility to NK cell-
mediated lysis. This effect was reversed by neutralizing NKG2D antibodies, confirming that 
enhanced lysis upon miRNA silencing was mediated through the NKG2D system. Hypoxia, a 
hallmark of glioblastomas in vivo, down-regulated the expression of NKG2DL on glioma 
cells, associated with reduced susceptibility to NK cell-mediated lysis. This process, 
however, was not mediated through any of the examined miRNA. Accordingly, both hypoxia 
and the expression of miRNA targeting NKG2DL may contribute to the immune evasion of 
glioma cells at the level of the NKG2D recognition pathway. Targeting miRNA may 
therefore represent a novel approach to increase the immunogenicity of glioblastoma. 
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INTRODUCTION 
 
Glioblastomas are intrinsic tumors of the brain with a poor prognosis despite comprehensive 
therapeutic strategies [1]. They are characterized by diffuse infiltration of the healthy brain, 
well-adapted to a hypoxic environment and poorly immunogenic, precluding potent anti-
tumor immune responses. Overcoming the lack of immunogenicity of glioma cells may help 
to exploit the immune system as a therapeutic weapon against these tumors. However, this 
will only be feasible based on a deeper understanding of the underlying mechanisms that 
preclude active immune responses. Glioma cells can interact and activate immune cells 
through ligands for activating receptors. One of the most prominent activating NK cell 
receptors investigated in the context of glioma is NKG2D, a receptor that also provides 
costimulatory signals to cytotoxic T cells [2]. Engagement of NKG2D initiates a perforin-
dependent immune attack [3]. NKG2D recognizes different MHC class I-homologous 
ligands (NKG2DL), including the MHC class I-chain related molecules A (MICA) and B 
(MICB) and the UL16-binding proteins (ULBP)1-6 [4, 5], which are also present on the 
surface of glioma cells [6]. However, the expression of NKG2DL by glioma cells is 
counteracted by different glioma-derived mechanisms that impede glioma cell recognition by 
immune cells. The NKG2D system is suppressed by transforming growth factor (TGF)-, a 
master immunosuppressive cytokine expressed by glioma cells, by at least three mechanisms: 
TGF- (i) down-regulates the expression of NKG2D on immune effector cells, (ii) reduces 
MICA and ULBP2 expression levels on the surface of glioma cells [7-9], and promotes 
NKG2DL protein cleavage from the cell surface in a metalloproteinase-dependent manner 
[8].  
microRNAs (miRNA), small non-coding RNA molecules that control numerous cellular 
mechanisms by inhibition of translation and/or enhanced degradation of specific mRNA, are 
involved in the regulation of NKG2DL expression in colon and prostate cancer cells as well 
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as melanoma [10-12]. In the context of gliomas and most other tumor entities, altered 
miRNA expression contributes to the malignant phenotype through deregulation of gene 
expression at the post-transcriptional level [13]. Here, we characterized the role of miRNA in 
the regulation of NKG2DL expression in glioma cells as well as their functional impact for 
the immunogenicity of these tumors.   
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RESULTS 
 
NKG2DL are expressed in LTC and GIC 
We have previously shown that NKG2DL are present on the cell surface of glioma long-term 
cell lines (LTC) [6]. Here, we assessed the expression of five different NKG2DL on glioma-
initiating cell (GIC) lines and confirmed their expression in the LTC lines LNT-229, LN-308, 
T98G and U87MG. Staining with monoclonal antibodies to MICA, MICB, ULBP1, ULBP2 
or ULBP3 and subsequent analysis by flow cytometry (exemplified in Fig. 1A) demonstrated 
the presence of most NKG2DL on the surface of the tumor cells (Fig. 1B). Overall, higher 
expression levels were noted in LTC than in GIC.  
 
Human glioma cells express putative NKG2DL-targeting miRNA in vitro and in vivo 
Based on the description of NKG2DL-regulating miRNA in cancer cell lines as well as in 
silico-based prediction using TargetScan and miRanda (www.targetscan.org; 
www.microRNA.org; [10, 14]), we selected six miRNA candidates as putative regulators of 
different NKG2DL in glioma cells. Three of these, miR-20a, miR-93 and miR-106b, were 
detected in all glioma cell lines assessed, with miR-93 being most abundantly expressed (Fig. 
1C). Three other candidate miRNA for NKG2DL regulation, miR-302, miR-372 and miR-
373, were investigated but not detected in any cell line examined. We also assessed the 
expression of all six candidate miRNA in vivo using tissue specimens of gliomas of different 
WHO grades. TaqMan
TM 
Array MicroRNA card analysis confirmed the expression of miR-
20a, miR-93 and miR-106b in human gliomas in vivo (Fig. 1D). Looking specifically at 
gliomas of different WHO grade, miR-93 expression levels were higher in any glioma 
compared to normal brain whereas for miR-20a and miR-106b a mixed expression pattern 
was observed (Fig. 1D). Consistent with the in vitro findings, miR-302, miR-372 and miR-
373 were not detected in any glioma tumor sample. Thus, we focused for all subsequent 
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studies on the broadly expressed miR-20a, miR-93 and miR-106b. 
 
LNA-mediated miRNA silencing up-regulates NKG2DL cell surface expression 
In order to assess the influence of the candidate miRNA on NKG2DL expression, we used 
LNA inhibitors to silence miR-20a, miR-93 or miR-106b expression in glioma cells. The 
effect of tumor cell exposure to LNA molecules on miRNA expression levels was evaluated 
by real-time PCR at different time points. As shown in Fig. 2A, LNA treatment inhibited 
miRNA expression in LNT-229 and LN-308 cells at 48 h and 72 h after transfection. A 
similar down-regulation was achieved upon exposure to LNA inhibitors in the GIC lines T-
269 and T-325 (Fig. 2B). In general, LNA molecules, regarded as target-specific, had most 
prominent effects on their target miRNA, however, we also observed cross-inhibition among 
miR-20a, miR-93 and miR-106b. These effects are likely due to the fact that all 3 miRNA 
share the same seed sequence (nucleotides 2 to 8). The combination of all 3 LNA inhibitors 
resulted in a strong down-regulation of all miRNA of interest (Fig. 2C). However, the 
combination of all 3 LNA inhibitors did not result in a stronger reduction of one of the 
miRNA candidates compared to treatment with a single specific LNA inhibitor as shown in 
Fig. 2A. As a next step, glioma cells, exposed to LNA inhibitors were analyzed for the cell-
surface expression of NKG2DL at different time-points after transfection using flow 
cytometry. LNA treatment resulted in an increase of NKG2DL on the cell surface of LNT-
229 and LN-308 cells (Fig. 3A). Although showing the same trend as LNA 20 and LNA 93, 
LNA 106b-induced changes were not statistically significant. The triple combination of 
LNAs was not more efficient in the up-regulation of NKG2DL than single LNA molecules 
(data not shown). Furthermore, we detected only minor changes in NKG2DL cell surface 
levels of GIC lines except for ULBP3, which was elevated upon exposure to LNA 93 in T-
269 cells (Suppl. Fig. 1). In line with the findings obtained with LNA inhibitors, treatment of 
LNT-229 cells with a miR-93 mimic decreased the cell surface expression of MICA, MICB 
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and ULBP3 (Fig. 3B). Similar results were obtained when LN-308 cells were treated with 
miR-93 mimics. Up-regulation of NKG2DL protein levels upon LNA treatment was not 
associated with an increase of NKG2DL transcripts suggesting that the observed effect on 
NKG2DL protein is due to translational repression and not caused by altered mRNA stability 
(Fig. 3C and data not shown). Next, we confirmed the specific interaction between a 
candidate miRNA and the 3’UTR of selected NKG2DL. The 3’UTR of MICA was cloned 
into the pMIR-RL dual luciferase vector. LN-308 glioma cells were co-transfected with 
reporter plasmid and miR-93 mimic or LNA 93 as indicated in the methods section. 
Transfection with the miR-93 mimic resulted in decreased reporter activity indicating that 
miR-93 interacts with the 3’UTR of MICA. Consequently, exposure to LNA 93 increased the 
activity of the reporter system suggesting an inhibitory activity of the LNA molecules on 
endogenous miR-93 in LN-308 cells (Fig. 3D). Similarly, exposure to the miR-93 mimic 
down-regulated MICA 3’UTR reporter activity in LNT-229 and T98G glioma cells (data not 
shown) corroborating the finding of a direct inhibitory effect of miR-93 on the 3’UTR of 
MICA. 
 
NK cell-mediated cytotoxicity in vitro is enhanced by inhibition of NKG2DL-targeting 
miRNA 
Next we determined the functional role of miRNA that control NKG2DL expression for the 
immunogenicity of glioma cells. As shown in Fig. 3A, the most prominent effects on 
NKG2DL expression were obtained after modulation of miR-93 activity. Accordingly, LAK 
cells were used as effector cells in a killing assay with LNT-229 or LN-308 cells pre-exposed 
to either control or LNA 93 molecules. Treatment with LNA 93 resulted in significantly 
increased immune cell-mediated lysis compared to control LNA-treated cells (Fig. 4A and B). 
To confirm these findings, we treated both cell lines with LNA 20a, which had also resulted 
in a significant upregulation of NKG2DL (Fig. 3A). Again, an increase in immune cell-
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mediated cytolysis was observed (Suppl. Fig. 2). The specific modulation of glioma cell 
immunogenicity was further corroborated by exposure of LNT-229 cells to miR-93 mimics, 
which resulted in reduced immune cell killing (Fig. 4C). Finally, we determined whether the 
increased glioma cell immunogenicity depends on the induction of NKG2DL in response to 
LNA treatment. Pre-incubation of LAK cells with NKG2D blocking antibodies reversed the 
enhanced susceptibility of LNT-229 glioma cells to immune cell killing upon LNA 93 
exposure, indicating that the observed effects are indeed mediated through a modulation of 
the NKG2D system. Conversely, when NKG2DL expression was reduced by miR-93 mimics, 
NKG2D blocking antibodies no longer decreased residual lysis (Fig. 4D).  
 
Hypoxia contributes to glioma immune escape through NKG2DL down-regulation in a 
miRNA-independent manner 
Hypoxia is a hallmark of high-grade gliomas and has been proposed to support glioma-
induced immunosuppression [15]. We therefore tested whether hypoxia modulates NKG2DL 
expression and whether such an effect is mediated by altered miRNA expression. LNT-229, 
LN-308 or T-269 cells were cultured under normal or hypoxic conditions for 24, 48 or 72 h. 
Up-regulation of CAIX confirmed that cells became hypoxic (Suppl. Fig. 3). We observed a 
sustained hypoxia-dependent down-regulation of MICA, MICB, ULBP2 and ULBP3 
transcripts in all 3 cell lines (Fig. 5A). Down-regulation on the protein level at the cell 
surface was confirmed by flow cytometry (Fig. 5B). However, this decrease in NKG2DL 
expression was not accompanied by increased miR-20a, miR-93 or miR-106b expression 
(Fig. 5C). In contrast, some miRNA were even down-regulated in hypoxia suggesting that 
hypoxia-induced repression of NKG2DL levels is not mediated through increased expression 
levels of the three candidate miRNA. When LNT-229 cells were cultured under hypoxic 
conditions for 48 h, they became significantly more resistant to immune cell lysis than cells 
that had been cultured under standard conditions (Fig. 5D). A similar, albeit less pronounced 
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effect, was found for LN-308 cells (data not shown), highlighting the contribution of hypoxia 
to the immune evasion of glioma cells. Pre-incubation of effector cells with anti-NKG2D 
blocking antibody resulted in a reduction of specific lysis to a similar extent than the effect 
observed for target cells that were kept under hypoxic conditions before lysis. NKG2D 
blocking antibodies further decreased the sensitivity of hypoxic target cells to immune cell 
killing, albeit to a lesser extent than in normoxic conditions reflecting the activity of residual 
NKG2DL expression in hypoxia (Suppl. Fig. 4).  
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DISCUSSION 
 
The treatment of glioblastoma has been challenging and many therapeutic approaches have 
largely failed including the administration of anti-angiogenic drugs, which do not prolong 
overall survival [16, 17]. Therefore, there is a continuous interest in defining novel molecular 
targets and strategies that may results in more encouraging results. The brain has been called 
an ‘immunoprivileged site’ because of several factors such as the presence of the blood-brain 
barrier and the lack of professional antigen-presenting cells that hamper immune responses. 
However, as can be observed in some pathological conditions such as inflammatory diseases, 
powerful immunological reactions occur in the central nervous system. Based on these 
considerations, therapeutic approaches aiming at exploiting the immune system against brain 
tumors hold promise and have gained increasing interest within the last years. However, 
malignant brain tumors and foremost glioblastoma are characterized by a variety of tumor-
derived mechanisms contributing to their immune escape [18]. Overcoming the lack of 
immunogenicity is a prerequisite for effective anti-tumor immune responses. Here, we 
characterized the regulation of the expression of ligands to one of the most prominent 
activating immune cell receptors, that is, NKG2D. Overall, constitutive NKG2DL expression 
by glioma cells is too low to efficiently promote immune cell activation in vivo [6]. We 
speculated that miRNA contribute to the down-regulation of NKG2DL expression on glioma 
cells. First, we identified the expression of three candidate miRNA, miR-20a, miR-93 and 
miR-106b, pre-selected by literature search as well as TargetScan and miRanda interrogation 
[10, 14], which may regulate NKG2DL expression (Fig. 1C). In contrast, three additional 
candidate miRNA were not detected in any cell line. These findings were corroborated by an 
analysis of fresh-frozen glioma tissue, which also revealed the expression of the first three 
candidates but not of the other three miRNA (Fig. 1D), confirming the reliability of the 
findings in in vitro cultured cell lines. We next sought to determine the functional impact of 
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the three candidate miRNA on NKG2DL levels on the surface of glioma cells. To this end, 
we used LNA molecules to antagonize the function of single miRNA candiates which 
resulted in a strong down-regulation of the respective miRNA. However, we also noticed 
overlapping effects of the LNA molecules on the other two miRNA, which can be explained 
by the seed sequence which is shared by all 3 miRNA candidates (Fig. 2A-C). Flow 
cytometric analysis of glioma cells exposed to LNA revealed enhanced surface expression of 
NKG2DL (Fig. 3A). In line with these findings, treatment of glioma cells with miR-93 
mimic decreased the expression of MICA and MICB (Fig. 3B). The specific interaction 
between endogenous miR-93 and the 3’UTR of MICA was demonstrated with an appropriate 
reporter assay system (Fig. 3D). However, since miRNA typically target numerous gene 
transcripts, the observed NKG2DL regulation may not only originate from direct interaction 
with the 3’UTR but also result from posttranscriptional and posttranslational mechanisms 
which are influenced by the examined miRNA. In summary, our findings indicate that 
NKG2DL are indeed controlled by miRNA in glioma cells, a mechanism which has also 
been described for other tumor cells [10-12]. Only minor changes in NKG2DL cell surface 
expression of GIC were detected upon LNA treatment, suggesting that NKG2DL levels are 
regulated rather on a transcriptional or posttranslational level in these cultures [7, 8], but not 
by the miRNA examined here. The upregulation of NKG2DL protein levels upon LNA 
treatment in LTC was not associated with an increase of NKG2DL transcripts suggesting that 
the observed effect on NKG2DL protein is due to a translational repression and not caused 
by altered mRNA stability. Most importantly, we confirmed the functional importance of 
miRNA-dependent regulation of NKG2DL in glioma cells using immune cell lysis assays 
(Fig. 4A-C). When the NKG2D system was inhibited with specific antibodies, the LNA-
mediated increase in immune cell lysis was abrogated, indicating that the observed effects are 
indeed mediated through a miRNA-dependent modulation of the NKG2D system (Fig. 4D). 
These findings corroborate the functional impact of the NKG2D system for the interaction 
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between glioma cells and the immune system [6, 9]. Therapeutic strategies aiming at 
exploiting NK cells as effector cells against gliomas have shown promising results in 
preclinical studies [19, 20]. Our results provide additional evidence for the importance of NK 
cells for tumor surveillance and support the further investigation of NK cell-based strategies 
against these tumors [19, 21-24]. 
Finally, we aimed at determining the influence of hypoxia, a hallmark of glioblastoma, on the 
set of miRNA examined here. miRNA expression can be induced by hypoxia [25] and 
hypoxia contributes to the immune escape of gliomas in a signal transducer and activator of 
transcription 3 (STAT3)-dependent manner via induction of regulatory T cells [15]. Our 
experiments reveal hypoxia-mediated down-regulation of NKG2DL expression as an 
additional mechanism which contributes to the immune evasion of these tumors (Fig. 5). An 
effect of hypoxia on MICA levels had been shown before in prostate and osteosarcoma cell 
lines [26, 27]. Our experiments demonstrate a pronounced effect of hypoxia on different 
NKG2DL and reduced immunogenicity as a functional consequence. However, hypoxia-
dependent NKG2DL regulation was not mediated through any of the miRNA examined in 
our cell lines.  
In summary, our study highlights the contribution of miRNA to the impaired immunogenicity 
of glioma cells. Given the rapidly evolving techniques which allow for an in vivo targeting of 
miRNA [28], inhibition of the miRNA described in this project may be exploited as an 
immunotherapeutic strategy against glioblastoma. 
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MATERIALS AND METHODS 
 
Cells and reagents 
The human glioma long-term cell lines (LTC) LN-18, LNT-229 and LN-308 were kindly 
provided by N. de Tribolet (Lausanne, Switzerland). U87MG and T98G glioma cells were 
purchased from the American Type Culture Collection. The GIC sphere cultures S-24, T-269 
and T-325 were generated as previously described [29]. The GS-2 and GS-9 GIC lines were 
kindly provided by K. Lamszus [30]. All cell lines were authentified by DNA typing at the 
Leibniz-Institut DSMZ GmbH (Braunschweig, Germany). LTC growing as adherent 
phenotype were maintained in Dulbecco’s modified eagle medium (DMEM, Invitrogen, Life 
Technologies, Carlsbad, CA), containing 10% fetal calf serum (FCS) (VWR Lonza, Leighton 
Buzzard, UK) and supplemented with 2 mM glutamine (Invitrogen, Life Technologies), in a 
5% CO2 incubator at 37ºC. GIC were maintained as sphere cultures in Neurobasal A medium 
(Invitrogen, Life Technologies) supplemented with EGF 10 ng/ml, FGF 10 ng/ml (Peprotech, 
Rocky Hill, NJ), Heparin 31.5 U/ml (Sigma Aldrich, St. Louis, MO), 1% Glutamax 
(Invitrogen, Life Technologies) and 2% B27 (Invitrogen, Life Technologies). Cells were 
detached with Accutase (Gibco, Life Technologies, Carlsbad, CA). When hypoxic conditions 
were needed, cells were kept in a hypoxia chamber adjusted to 5% CO2 and 1% O2 at 37˚C. 
Buffy coats (Blutspende Zurich, Switzerland) were used for the generation of lymphokine-
activated killers (LAK) cells. For the selection of CD56+ NK cells, appropriate beads for 
magnetic cell sorting (MACS, Miltenyi Biotech, Bergisch Gladbach, Germany) were used. 
Immune cells were kept in RPMI 1640 (Gibco, Life Technologies) supplemented with 9% 
FCS, 2 mM glutamine (Gibco, Life Technologies), and 1,000 U/ml of recombinant human 
interleukin (IL)-2 (Peprotech) in 5% CO2 atmosphere and 37˚C. 
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MicroRNA expression analyses in primary glioma tissue samples 
Expression of the six selected candidate miRNA was investigated in primary glioma tissue 
samples from 79 patients, including seven patients with diffuse astrocytoma, World Health 
Organization (WHO) grade II (AII), 11 patients with anaplastic astrocytoma, WHO grade III 
(AAIII), eight patients with secondary glioblastoma, WHO grade IV (sGBIV) and 53 patients 
with primary glioblastomas, WHO grade IV (pGBIV). Investigation of these tumor samples 
was approved by the institutional review board of the Medical Faculty at Heinrich Heine 
University Düsseldorf (study number 3482). Total RNA was extracted from fresh-frozen 
tumor samples using ultracentrifugation as described [31]. Only tissue samples with a 
histologically estimated tumor cell content of 80% or more were used for RNA extraction. In 
addition to the tumor tissue specimens, we investigated RNA samples from eight non-
neoplastic control brain tissues. These were obtained from commercial sources (#540005 
from Stratagene, Cedar Creek, TX; #AM7962 from Ambion, Huntington, UK; #R1234051-
50, #R1234035-50, #R1234062-50, #R1234042-10, #R1234045-10, and #R1234078-50 from 
Biochain, Newark, CA). Analyses for miRNA expression were performed using the 
TaqMan
TM
 PCR-based miRNA microfluidic card system from Applied Biosystems (Life 
Technologies) according to the manufacturer's protocol. Expression values of each of the 
investigated candidate miRNA were normalized against four reference miRNA (miR-30a-5p, 
miR-30b, miR-30c, and miR-30d), which showed the most stable expression over all analyzed 
samples.  
 
Transient transfection 
Glioma cells were seeded at appropriate density for each cell line in 6-well plates or 6 cm 
tissue culture dishes (TPP, Trasadingen, Switzerland), allowed to attach overnight and 
transfected with 50 nM of LNA
TM
 (Exiqon, Vedbaek, Denmark) or MiRidian miRNA 
mimics (Dharmacon/Thermo Scientific, Lafayette, CO) specific for a certain miRNA. 
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Metafectene Pro (Biontex, Martinsried, Germany) was used as a transfection reagent. To 
exclude any unspecific effects exerted by the transfection procedure, all experiments 
including LNA inhibitors or miRNA mimics were performed with scrambled LNA or mimic 
molecules, which had no effect on the constitutive miRNA expression, as a control. 
Subsequently, 24 h after the start of transfection, the medium was changed and the cells were 
kept in experimental conditions for different times as indicated.  
 
Real-time polymerase chain reaction (PCR) 
Total RNA was prepared using the NucleoSpin® kit (Macherey Nagel GmbH, Düren, 
Germany). Complementary DNA was prepared using the iScript® kit (BioRad, Hercules, 
CA). For real-time PCR, gene expression was measured in an Applied Biosystems 7300 
Real-Time PCR System using the ABI Prism 7000 Sequence Detection System (Applied 
Biosystems, Carlsbad, CA) with SYBR Green ROX Mix (Thermo Scientific) and primers 
(Microsynth AG, Balgach, Switzerland) at a final concentration of 0.4 µM.  
GAPDH primers have been described by Carraro et al. [32], and carbonic anhydrase IX 
(CAIX) by Nytko et al. [33]. Other primer sequences were MICA fwd: 5'-
CCTTGGCCATGAACGTCAGG-3', rev: 5'-CCTCTGAGGCCTCGCTGCG-3'; MICB fwd: 
5'-ACCTTGGCTATGAACGTCACA-3', rev: 5'-CCCTCTGAGACCTCGCTGCA-3'; 
ULBP2 fwd: 5'-TTACTTCTCAATGGGAGACTGT-3', rev: 5'-
TGTGCCTGAGGACATGGCGA-3'; ULBP3 fwd: 5'-CCTGATGCACAGGAAGAAGAG-
3', rev: 5'-TATGGCTTTGGGTTGAGC TAAG-3'.  
Total miRNA was prepared using the miRNeasy Mini Kit (Qiagen, Venlo, The Netherlands). 
Complementary DNA transcription from miRNA and subsequent real-time PCR-FAM 
detection was performed using specific TaqMan® probes (Applied Biosystems). The general 
conditions were 40 cycles at 95ºC/15 s and 60ºC/1 min. Relative quantification of gene 
expression was determined by comparison of threshold values. All results were normalized to 
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GAPDH for mRNA and to RNU48 for miRNA, and calculated with the CT method for 
relative quantification [34]. 
 
Flow cytometry 
For the examination of NKG2DL cell surface levels by flow cytometry, the following mouse 
monoclonal antibodies were used at a final concentration of 10 g/ml: AMO1 (MICA), 
BMO1 (MICB), AUMO1 (ULBP1), BUMO1 (ULBP2) and CUMO3 (ULBP3) [35]. Mouse 
monoclonal IgG1- (Sigma-Aldrich) was used as isotype control. Following incubation with 
the primary antibody, a polyclonal goat anti-mouse immunoglobulins/RPE 
(DakoCytomation, Forth Collins, CO, 1:50) was applied. For the exclusion of dead cells, 
staining with TO-PRO-3 iodide (642/661) (Life Technologies) (0.1 µM) was performed right 
before acquisition of samples. Fluorescence was detected in a CyanADP flow cytometer 
(Beckman Coulter, Nyon, Switzerland). Specific fluorescence indexes (SFI) were calculated 
by dividing median fluorescence obtained with specific antibody by median fluorescence 
obtained with control antibody. 
 
Immune cell lysis assay 
Target cells were detached and labeled using the PKH26 Red Fluorescent Cell Linker Kit for 
general cell membrane staining (Sigma-Aldrich). Incubation with effector cells was 
performed in a final volume of 550 µl of complete RPMI, at 37˚C for 1.5 h in case of LNT-
229 and 3.5 h in case of LN-308. Various effector:target (E:T) ratios were used as indicated. 
In order to block NKG2D, immune effector cells were pre-incubated with mouse anti-human 
NKG2D LEAF purified antibody (Biolegend, San Diego, CA) for 1.5 h (0.5 g/ml), and 
during the lysis incubation time. Effector cells were used when the viability was > 90% on 
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Vicell counting (Beckman Coulter). Dead cell staining was performed right before 
acquisition of samples with 0.1 µM TO-PRO-3 iodide. 
 
3’UTR luciferase gene reporter assay 
3’UTR from MICA was cloned into the pMIR-RL dual luciferase vector [36]. Restriction 
enzymes used for cloning were SpeI and PmeI (New England Biolabs, Ipswich, MA). The 
sequence of the primers (Microsynth AG) used for cloning was: fwd: 5’-
ACTAGTGCAGCTGGGATTCAATT-3’, rev: 5’-GTTTAAACACGCCTCATATCTAC-3’; 
Dual luciferase assays were performed using 10,000 cells per well in a 96-well plate. 
Following attachment overnight, the cells were co-transfected with 20 ng of the respective 
reporter construct and 50 nM of LNA molecules or miRNA mimics. Firefly luciferase 
activity was normalized to constitutive renilla luciferase activity. 
 
Statistics 
Data are expressed as mean and standard error of the mean. The experiments shown were 
repeated three times with similar results. Analysis of significance was performed using the 
one sample t-test for data expressed as %, Student’s t-test for miRNA expression analysis 
and two way ANOVA for lysis assays (GraphPad Prism 5, La Jolla, CA) (* p<0.05). 
Statistical evaluation of miRNA expression in different groups of astrocytic gliomas and non-
neoplastic brain tissues was performed using the Kruskal-Wallis test with Dunn’s correction 
for multiple testing. 
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Figure legends 
 
Fig. 1. NKG2DL and NKG2DL-regulating miRNA are expressed by LTC and GIC. A, B. 
NKG2DL expression was assessed in a panel of glioblastoma cell lines. The levels of MICA, 
MICB, ULBP1, ULBP2 and ULBP3 on the cell surface of T-325 cells are shown in A 
(specific antibody light grey; isotype control dark grey). Specific fluorescence indexes (SFI) 
are indicated in B. C. miR-20a, miR-93 and miR-106b levels were analyzed by real-time PCR 
using RNU48 as reference. Relative expression levels are shown. D. The expression of three 
candidate miRNA in tissue samples of normal brain and gliomas of different WHO grades 
were assessed using TaqManTM microfluidic card analyses. Normalized relative expression 
values are indicated for each tumor group (AII, low-grade astrocytoma, AAIII, anaplastic 
astrocytoma, pGBIV and sGBIV, primary and secondary glioblastoma) and non-neoplastic 
brain tissue sample (NB). Boxplots indicate the median expression levels as well as upper 75th 
percentiles and lower 25th percentiles. Whiskers represent the minimal and maximal 
expression values, respectively. Statistical comparisons between groups were performed with 
the Kruskal-Wallis test and Dunn’s correction for multiple testing (** p<0.01; *** p<0.001). 
 
Fig. 2. LNA molecules down-regulate miRNA expression in glioma cells. A. LNT-229 or 
LN-308 cells were exposed to LNA molecules specific for single miRNA inhibition or 
containing a scrambled control sequence. miR-20a, miR-93 and miR-106b expression levels 
were determined by real-time PCR. B. T-269 and T-325 GIC cells were treated and analyzed 
as in (A) (* p<0.05). C. LNT-229 or LN-308 cells were exposed to a LNA triple combination 
(25 nM for each LNA, 75 nM in total). miRNA levels were assessed by real-time PCR.  
 
Fig. 3. LNA-mediated miRNA inhibition results in increased NKG2DL expression. A. 
LNT-229 or LN-308 glioma cells were exposed to single specific LNAs or scrambled control 
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LNA molecules at 50 nM. The cells were harvested and analyzed after 48 h for NKG2DL cell 
surface expression by flow cytometry. Expression is shown as % of control for every 
NKG2DL which displayed an increased expression with at least one LNA inhibitor (* 
p<0.05). B. LNT-229 cells or LN-308 were transfected with miR-93 mimic or scrambled 
control at a concentration of 50 nM and NKG2DL expression was analyzed by flow 
cytometry. Expression is shown as % of reduction respect to control mimic in 4 independent 
experiments (* p<0.05). C. The cells were treated as in (A) and analyzed for NKG2DL mRNA 
expression by qPCR after 72 h. D. Direct targeting of the 3’UTR of MICA was analyzed by 
luciferase reporter constructs using LN-308 cells. The cells were co-transfected with the 
reporter plasmid and miR-93 mimic, LNA 93 or the corresponding controls for 24 h. Glioma 
cells transfected with the empty reporter construct (pMiR-RL) were used as control (* 
p<0.05). 
 
Fig. 4. LNA-mediated miRNA inhibition enhances glioma cell susceptibility to immune 
cell lysis. A, B. LAK cells were used in a 3.5 h immune cell lysis assay with LNT-229 (A) or 
LN-308 cells (B), pretreated with control or LNA 93 molecules for 48 h, as target cells. Data 
are expressed as specific lysis at different effector:target (E:T) ratios for independent 
experiments (* p<0.05, ANOVA). C. LNT-229 cells were exposed to miR-93 mimics (mimic-
93) or the respective control molecules and subsequently used as target cells in an immune 
cell killing assay as in (A). D. LAK cells were pre-incubated with anti-NKG2D antibody or 
isotype control for 1.5 h and subsequently used as effector cells in a killing assay as in (A) 
against LNT-229 target cells pre-exposed to LNA 93 or miR-93 mimic at an E:T ratio of 20:1. 
Data are expressed as % of lysis of cells treated with control LNA plus isotype antibody (* 
p<0.05, n.s.= not significant).   
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Fig. 5. Hypoxia reduces NKG2DL expression on glioma cells in a miRNA-independent 
manner. A. Glioma cells were cultured under normoxic or hypoxic conditions for 24, 48 and 
72 h and subsequently assessed for NKG2DL expression by real-time PCR (* p<0.05). B. The 
cells were cultured under normoxic oder hypoxic (Hx) conditions as indicated and assessed 
for NKG2DL levels at the cell surface by flow cytometry (* p<0.05). C. The cells were 
treated as in (B) and miRNA expression levels were determined by real-time PCR using 
RNU48 as a control (* p<0.05). D. LNT-229 glioma cells were cultured under hypoxia or 
normoxia for 48 h and subsequently used as targets in a LAK cell lysis assay. Data are 
expressed as specific lysis at different E:T ratios from independent experiments (* p<0.05, 
ANOVA). 
 
Supplementary Fig. 1. LNA-mediated miRNA inhibition does not affect NKG2DL 
expression in GIC. T-269 or T-325 glioma cells were exposed to single LNAs at 50 nM. The 
cells were harvested and analyzed after 48 h for NKG2DL cell surface expression by flow 
cytometry.  
 
Supplementary Fig. 2. LNA-mediated miRNA inhibition enhances glioma cell 
susceptibility to immune cell lysis. LAK cells were used in a 3.5 h immune cell lysis assay 
with LNT-229 or LN-308 cells, pretreated with control or LNA 20a molecules for 48 h, as 
target cells. Data are expressed as specific lysis at different effector:target (E:T) ratios.  
 
Supplementary Fig. 3. Confirmation of hypoxic conditions by CAIX expression. Glioma 
cells were cultured under normoxic or hypoxic conditions as indicated and subsequently 
assessed for CAIX mRNA expression by qPCR. Values are normalized to the respective 
control incubated in standard oxygen concentration. 
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Supplementary Fig. 4. Reduced immune cell lysis of hypoxic targets is partially 
mediated through NKG2D signaling. LAK cells were pre-incubated with anti-NKG2D 
antibody or isotype control before their use as effector cells in a killing assay at an E:T ratio 
of 20:1. LNT-229 target cells were cultured under standard oxygen conditions or in hypoxia 
(1%) for 48 h prior to the experiment.  







